Treatment of immune thrombocytopenia in Australian adults: A multicenter retrospective observational study

CONCLUSION: A wide range of "second-line" agents were used across centers with variable response rates and side effect profiles. Findings suggest greater effectiveness of rituximab and TPO-A, supporting their use earlier in the treatment course of patients with ITP across Australia.PMID:36186101 | PMC:PMC9483174 | DOI:10.1002/rth2.12792
Source: Thrombosis and Haemostasis - Category: Hematology Authors: Source Type: research